<DOC>
	<DOCNO>NCT02738008</DOCNO>
	<brief_summary>Chronic HBV patient receive 9 dos open-label ARC-520 every 4 week evaluate safety efficacy .</brief_summary>
	<brief_title>Extension Study Safety Efficacy Multi-dose Intravenous ARC-520 Patients With Chronic Hepatitis B ( HBV ) Infection</brief_title>
	<detailed_description>Open-label , multi-center extension study intravenous ARC-520 combination entecavir tenofovir patient chronic HBV infection . Patients successfully complete Heparc-2002/Heparc-2003 study respond therapy eligible participate . Patients sign Human Research Ethics Committee approve informed consent meet protocol eligibility criterion continue receive daily oral entecavir tenofovir IV injection ARC-520 . Study visit occur every 4 week total 9 visit monitor ARC-520 administration . Patients undergo following evaluation regular interval study : medical history , physical examination , vital sign measurement ( blood pressure , heart rate , respiratory rate temperature ) , weight , adverse event ( AEs ) , 12-lead electrocardiogram ( ECGs ) , concomitant medication , blood sample collection hematology , coagulation , chemistry , creatine kinase , troponin , hemoglobin A1c , exploratory pharmacodynamic ( PD ) measure , urinalysis , HBV serology , immunogenicity , pregnancy test female childbearing potential . Patients monitor HBV virology , AEs , exploratory PD measure total 24 week last dose ARC-520 .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<criteria>Patient show ½ log great reduction serum HBsAg level baseline day 71 ± 3 day 99 ± 3 primary Heparc2002 Heparc2003 study Able first dose within 2 month day 113 endofstudy visit primary Heparc2002 Heparc2003 study Able provide write informed consent prior performance study specific procedure . Have abnormality 12lead ECG assessment , opinion investigator , may compromise patient safety Willing able comply study assessment adhere protocol schedule . Have new abnormal find clinical relevance screen evaluation . Using 2 effective method contraception ( double barrier contraception hormonal contraceptive along barrier contraceptive ) ( male female partner ) study 3 month follow last dose ( ARC 520 ) . Pregnant lactate Acute sign hepatitis/other infection within 4 week screen and/or screen examination . Use prescription medication ( include anticoagulant ) within 14 day prior administration ARC520 Has major surgery within 3 month screen . Has evidence severe systemic acute inflammation , sepsis , hemolysis . Diagnosed significant psychiatric disorder would prevent participation study . Unable unwilling return schedule study visit . Has condition , opinion investigator , would render patient unsuitable enrollment , could interfere his/her participation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>